Back to Search
Start Over
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
- Source :
- International Journal of Molecular Sciences; Volume 18; Issue 5; Pages: 906, International Journal of Molecular Sciences
- Publication Year :
- 2017
- Publisher :
- MDPI AG, 2017.
-
Abstract
- The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 90 mg of ledipasvir plus 400 mg of sofosbuvir daily. Sustained virological response at 12 weeks post-treatment (SVR12) was achieved in 236 of 240 (98.3%) patients. Among treatment-naïve patients, SVR12 was achieved in 136 of 138 (98.6%) patients, and among treatment-experienced patients, SVR12 was achieved in 100 of 102 (98.0%) patients. In patients previously treated with peginterferon plus ribavirin with various HCV NS3/4A inhibitors, 100% SVR rates (25/25) were achieved. Two relapsers had HCV NS5A resistance-associated variants (RAVs), but no HCV NS5B-S282 was observed after they relapsed. We experienced two patients with cardiac events during treatment. In conclusion, combination of ledipasvir plus sofosbuvir for 12 weeks is a potential therapy for HCV GT1 patients. Caution is needed for HCV NS5A RAVs, which were selected by HCV NS5A inhibitors and cardiac adverse events.
- Subjects :
- hepatitis C virus
Male
ledipasvir
Sofosbuvir
genotype 1
NS3/4A inhibitors
sofosbuvir
Hepacivirus
Viral Nonstructural Proteins
medicine.disease_cause
Gastroenterology
Polyethylene Glycols
Virological response
chemistry.chemical_compound
0302 clinical medicine
Japan
Spectroscopy
Intracellular Signaling Peptides and Proteins
virus diseases
General Medicine
Middle Aged
Recombinant Proteins
Computer Science Applications
Treatment Outcome
030220 oncology & carcinogenesis
RNA, Viral
Drug Therapy, Combination
Female
030211 gastroenterology & hepatology
medicine.drug
Ledipasvir
medicine.medical_specialty
Genotype
Hepatitis C virus
Antiviral Agents
Polymorphism, Single Nucleotide
Article
Drug Administration Schedule
Catalysis
Inorganic Chemistry
03 medical and health sciences
Asian People
Internal medicine
Drug Resistance, Viral
Ribavirin
medicine
Humans
Physical and Theoretical Chemistry
Adverse effect
NS5A
Molecular Biology
Aged
Retrospective Studies
Fluorenes
business.industry
Interleukins
Organic Chemistry
Interferon-alpha
Retrospective cohort study
Hepatitis C, Chronic
Virology
digestive system diseases
chemistry
Benzimidazoles
Interferons
Carrier Proteins
business
Subjects
Details
- ISSN :
- 14220067
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- International Journal of Molecular Sciences
- Accession number :
- edsair.doi.dedup.....c087a70a46c60adf369b56044e5897c7